Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
PDS Biotechnology is a clinical-stage immunotherapy company developing Versamune-based cancer vaccines, with lead candidate PDS0101 in Phase 2/3 trials for HPV-associated cancers and melanoma. The company has no commercial revenue, operates entirely on clinical trial execution and partnership potential, with survival dependent on capital raises and regulatory milestone achievement. Stock trades on binary clinical trial outcomes and partnership announcements.
PDS operates a classic biotech development model: raise capital through equity offerings and debt, fund clinical trials to generate safety/efficacy data, seek FDA approval, then monetize through direct commercialization or partnership deals. The Versamune platform technology aims to activate T-cell responses against cancer antigens. Value creation depends entirely on clinical trial success rates, regulatory approval probability, and partnership economics. Current burn rate estimated $25-35M annually with no offsetting revenue.
Phase 2/3 clinical trial data releases for PDS0101 in HPV-associated cancers (head/neck, cervical)
FDA regulatory interactions - IND approvals, Fast Track/Breakthrough designations, meeting outcomes
Partnership announcements with major pharma for co-development or commercialization rights
Equity financing announcements (dilutive but extends cash runway)
Competitive trial results from other HPV-targeted immunotherapies or checkpoint inhibitor combinations
Patent litigation outcomes or intellectual property developments around Versamune platform
Binary clinical trial risk - single Phase 3 failure could render company worthless given concentrated pipeline around PDS0101/Versamune platform
FDA regulatory pathway uncertainty for cancer vaccines - historically low approval rates for therapeutic vaccines versus checkpoint inhibitors
Competitive obsolescence risk from CAR-T, bispecific antibodies, and next-generation immunotherapies with stronger efficacy data
Healthcare policy risk around drug pricing legislation affecting future commercial economics and partnership valuations
Merck's Keytruda and BMS's Opdivo dominate HPV-associated cancer treatment with established efficacy - PDS must demonstrate superiority or complementary benefit
Well-funded competitors (Moderna, BioNTech) developing mRNA-based personalized cancer vaccines with platform advantages
Partnership risk - major pharma may prioritize internal programs or competing platforms over Versamune licensing
Negative $100.5% ROA and -$93.1% FCF yield indicate severe cash burn with no path to profitability before 2028 at earliest
Equity dilution risk - likely requires multiple capital raises before potential commercialization, diluting existing shareholders by 50%+ cumulatively
Going concern risk if clinical trials fail or capital markets close - company has limited non-dilutive financing options
1.90x debt/equity suggests some leverage that could become problematic if trials disappoint and refinancing is needed
low - Clinical trial timelines and FDA processes are largely insulated from GDP fluctuations. However, capital markets access for funding is highly cyclical. During recessions, biotech IPO/follow-on markets freeze, making capital raises difficult or impossible. Patient enrollment can slow modestly in severe downturns but is secondary concern.
High sensitivity through valuation multiple compression. Rising rates increase discount rates applied to distant future cash flows (post-2028), disproportionately hurting pre-revenue biotechs. Higher rates also reduce risk appetite for speculative growth stocks. Operationally, minimal direct impact as company has limited debt ($1.90 D/E ratio suggests some borrowing but small absolute amounts given market cap). Rate environment primarily affects ability to raise equity capital on favorable terms.
Moderate - Company depends on functioning capital markets to raise equity/debt for ongoing operations. Credit spread widening signals risk-off environment where speculative biotech financing becomes scarce or prohibitively dilutive. High-yield spreads above 500bps historically correlate with biotech funding freezes. Current 2.09x current ratio provides modest near-term buffer but insufficient for multi-year runway.
growth/speculative - Attracts biotech-focused hedge funds, venture investors, and retail speculators willing to accept binary outcomes for asymmetric upside. Not suitable for value or income investors given no earnings, dividends, or tangible book value. Momentum traders active around clinical data catalysts. Typical holder has high risk tolerance and portfolio diversification across multiple clinical-stage names.
high - Clinical-stage biotechs routinely experience 30-50% single-day moves on trial data. -51.5% one-year return and -44.5% six-month return reflect typical volatility. Implied volatility likely exceeds 80-100% around data readouts. Beta to broader market probably 1.5-2.0x, but idiosyncratic risk dominates systematic risk.